Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)

The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer.
Not Available
III
Crispens, Marta
NCT03398655
VICCGYN18180

Pembrolizumab in Treating Patients with Stage III-IV High-Risk Melanoma Before and After Surgery

This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better in treating melanoma.
Not Available
II
Davis, Elizabeth
NCT03698019
ECOGMELS1801

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Not Available
III
Iams, Wade
NCT03703297
VICCTHO1901

Ruxolitinib in Preventing Breast Cancer in Patients with High Risk and Precancerous Breast Lesions

This phase II trial studies how well ruxolitinib before surgery works in preventing breast cancer in patients with high risk and precancerous breast conditions. Ruxolitinib may changes the breast cell when administered to participants with precancerous breast conditions. Ruxolitinib may stop the growth of cells by blocking some of the enzymes needed for cell growth.
Not Available
II
Not Available
NCT02928978
VICCBRE1904

COLON MAP: Colorectal Molecular Atlas Project

Not Available
N/A
Shrubsole, Martha
VICCGI1905

A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors

The purpose of this study is to evaluate the tolerability and safety profile of ASP1948 when administered as a single agent and in combination with nivolumab in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1948 when administered as a single agent and in combination with nivolumab and determine the recommended Phase 2 dose (RP2D) of ASP1948 when administered as a single agent and in combination with nivolumab. This study will also evaluate the antitumor effect of ASP1948 when administered as a single agent and in combination with nivolumab.
Not Available
I
Horn, Leora
NCT03565445
VICCPHI1907

A Dose Escalation Study Of PF?06939999 In Participants With Advanced Or Metastatic Solid Tumors

This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
Not Available
I
Not Available
NCT03854227
VICCPHI1909

A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD

This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of EQ001 in subjects with Acute Graft Versus Host Disease (aGVHD).
Not Available
I/II
Jagasia, Madan
NCT03763318
VICCBMT1911

Itacitinib in Treating Patients with Low Risk Graft Versus Host Disease

This phase II trial studies how well itacitinib works in treating patients with low risk graft versus host disease. Graft versus host disease is the most common serious complication after bone marrow transplant. It occurs when donor immune cells (the graft) attack normal tissue in the recipient’s body. This inflammatory immune system attack can damage the skin, liver, stomach, and / or intestines. Itacitinib may help reduce the inflammation associated with graft versus host disease by blocking the enzymes associated with activating the inflammatory process.
Not Available
II
Kitko, Carrie
NCT03846479
VICCPED1912

ME-401 in Subjects With Follicular Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

This is the study of the PI3K? inhibitor ME-401 in subjects with relapsed / refractory follicular lymphoma after failure of at least 2 prior lines of systemic therapy
Not Available
II
Reddy, Nishitha
NCT03768505
VICCPCL1913

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: